Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma

Ribociclib is a specific cyclin dependent kinase (Cdk) 4/6 inhibitor that induces G(1) arrest by blocking the formation of cyclin D1-Cdk4/6 complex and inhibiting retinoblastoma (RB) phosphorylation. Cyclin D1 is overexpressed in over 90% of nasopharyngeal carcinoma (NPC) and CCND1 gene activation p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Chi-Hang, Ma, Brigette B. Y., Hui, Connie W. C., Lo, Kwok-Wai, Hui, Edwin P., Chan, Anthony T. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964240/
https://www.ncbi.nlm.nih.gov/pubmed/29789630
http://dx.doi.org/10.1038/s41598-018-26201-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964240/
https://www.ncbi.nlm.nih.gov/pubmed/29789630
http://dx.doi.org/10.1038/s41598-018-26201-1

Ejemplares similares